Dallas, TX - The Publisher of Daily OTC Stocks Newsletter (http://www.otcpicks.com/hotpicks.htm) and Free Red Hot Stock Picks presents the following penny stocks to watch today: Sino Fibre Communications Inc. (OTCBB: SFBE), Molecular Insight Pharmaceuticals Inc. (Nasdaq: MIPI) and PharmAthene Inc. (NYSE Amex: PIP).
SINO FIBRE COMMUNICATIONS (OTCBB: SFBE) "Up 114.29% on Friday"
Sino Fibre Communications, Inc. operates as a broadband carrier to provide services to the wholesale carrier and service provider segments of the broadband market in the People's Republic of China. The company markets and sells fiber optic backbone services of Sino-Con Telecomm Group., Ltd. (Sino-Con) to foreign telecommunications carriers and corporate users. Sino-Con's fiber optic backbone provides a fiber optic network within China that allows for long distance and local telephone services, Internet services, television services, and wireless LAN services. The company was founded in 1999. It was formerly known as Pacific Rim Solutions, Inc. and changed its name to Sino Fibre Communications, Inc. in 2006. Sino Fibre Communications is based in New York, New York.
MOLECULAR INSIGHT PHARMACEUTICALS (NASDAQ: MIPI) "Up 64.94% on Friday"
Molecular Insight Pharmaceuticals is a clinical-stage biopharmaceutical company and pioneer in molecular medicine. The Company is focused on the discovery and development of targeted therapeutic and imaging radiopharmaceuticals for use in oncology. Molecular Insight has five clinical-stage candidates in development.
PHARMATHENE INCORPORATED (AMEX: PIP) "Up 61.11% on Friday"
PharmAthene, Inc., a biodefense company, together with its subsidiaries, engages in the development and commercialization of medical countermeasures against biological and chemical weapons in the United States. Its product candidates include SparVax, a recombinant protective antigen (rPA) anthrax vaccine to protect against inhalation anthrax that has completed one Phase I and two Phase II clinical trials; and Valortim, a human monoclonal antibody to protect against and treat human inhalational anthrax, which has completed Phase I clinical trial. The company’s product candidates also include Protexia, a recombinant enzyme (butyrylcholinesterase), which mimics a natural bioscavenger for the prevention or treatment of nerve agent poisoning by organophosphate compounds, including nerve gases and pesticides. In addition, its product candidates include RypVax, a recombinant plague vaccine comprising separate recombinant F1 (rF1) and V (rV) antigens produced in Escherichia coli, which completed three Phase I human clinical trials; and rPA anthrax vaccine, which does not require refrigeration. The company’s customers include National Institute of Allergy and Infectious Diseases, the U.S. Department of Defense, Biomedical Advanced Research and Development Authority, and the U.S. National Institutes of Health. It has a collaboration agreement with Medarex, Inc. to develop and commercialize Valortim. PharmAthene, Inc. was founded in 2001 and is based in Annapolis, Maryland.
The stocks presented above are available in OTCPicks.com's Free Daily Email Newsletter. For daily penny stock alerts go to http://www.otcpicks.com/hotpicks.htm
Get the latest updates via Twitter at www.twitter.com/otcpicks or through Facebook - www.facebook.com/otcpicks.
Disclosure: OTCPicks.com has not been compensated by any of the companies covered in this release.
